Modernizing cell therapy manufacturing to reduce vein-to-vein times
The BioInsights Podcast
Chapters
0:49
How have you seen CAR-T cell therapies evolve over time?
3:00
What are the key challenges and priorities for CAR-T cell manufacture?
6:35
Why are the initial steps in apheresis or debulking important?
11:39
How does DCS microfluidics differ from other techniques?
14:37
How can DCS optimize the expansion of T cells?
16:56
Does cell separation impact subsequent genome editing steps?
21:12
Can manufacturing processes help ensure clinical efficacy?
More Info
The BioInsights Podcast
Modernizing cell therapy manufacturing to reduce vein-to-vein times
Jul 26, 2023 Season 2 Episode 8
David Backer, CEO Curate Biosciences

Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.